Semicarnazide-sensitive amine oxidase

Current status and perspectives

P. Mátyus, B. Dajka-Halász, A. Földi, N. Haider, D. Barlocco, K. Magyar

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Semicarbazide-sensitive amine-oxidase (SSAO) is present in various human tissues and in plasma. Oxidative deamination of short-chain aliphatic amines is catalyzed by this enzyme to afford the corresponding aldehydes, ammonia and hydrogen peroxide. Methylamine and aminoacetone have been recognized to be physiological substrates for SSAO. There are several pathological states where increased serum SSAO activity have been found, such as diabetes mellitus, congestive heart failure, multiple types of cerebral infarction, uraemia, and hepatic cirrhosis. The role of SSAO in pathophysiology of diabetes has been most extensively investigated. The elevated formation of the potentially cytotoxic products of the enzyme may contribute to the endothelial injury of blood vessels, resulting in the early development of severe atherosclerosis; it may also contribute to the pathogenesis of diabetic angiopathy. It is now suggested that SSAO inhibitors may prevent the development of atherosclerosis and diabetic complications as well. Inhibitors can be conveniently subdivided into the main groups of hydrazine derivatives, arylalkylamines, propenyl- and propargylamines, oxazolidinones, and haloalkylamines. Of them, aryl(alkyl)hydrazines, and 3-halo-2-phenylallylamines are generally very strong SSAO inhibitors. Most of these inhibitors of SSAO have been originally developed for other purposes, or they are simple chemical reagents with highly reactive structural element(s); these compounds have not been able to fulfil all criteria of high potency, selectivity, and acceptable toxicity. New potent compounds with selectivity and low toxicity are needed, which may prove useful tools for understanding the roles and function of SSAO, or they may even be valuable substances for treatment of various diseases.

Original languageEnglish
Pages (from-to)1285-1298
Number of pages14
JournalCurrent Medicinal Chemistry
Volume11
Issue number10
Publication statusPublished - May 2004

Fingerprint

Amine Oxidase (Copper-Containing)
Amines
Oxidoreductases
hydrazine
Medical problems
Toxicity
Atherosclerosis
Hydrazines
Oxazolidinones
Diabetic Angiopathies
Deamination
Uremia
Cerebral Infarction
Blood vessels
Diabetes Complications
Enzymes
Ammonia
Aldehydes
Chemical elements
Liver Cirrhosis

Keywords

  • Atherosclerosis
  • Diabetes
  • Haloalkylamines
  • Haloallylamines
  • Hydrazines
  • Inhibitors
  • Semicarbazide-sensitive amine oxidase (ssao)
  • VAP-1

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Mátyus, P., Dajka-Halász, B., Földi, A., Haider, N., Barlocco, D., & Magyar, K. (2004). Semicarnazide-sensitive amine oxidase: Current status and perspectives. Current Medicinal Chemistry, 11(10), 1285-1298.

Semicarnazide-sensitive amine oxidase : Current status and perspectives. / Mátyus, P.; Dajka-Halász, B.; Földi, A.; Haider, N.; Barlocco, D.; Magyar, K.

In: Current Medicinal Chemistry, Vol. 11, No. 10, 05.2004, p. 1285-1298.

Research output: Contribution to journalArticle

Mátyus, P, Dajka-Halász, B, Földi, A, Haider, N, Barlocco, D & Magyar, K 2004, 'Semicarnazide-sensitive amine oxidase: Current status and perspectives', Current Medicinal Chemistry, vol. 11, no. 10, pp. 1285-1298.
Mátyus P, Dajka-Halász B, Földi A, Haider N, Barlocco D, Magyar K. Semicarnazide-sensitive amine oxidase: Current status and perspectives. Current Medicinal Chemistry. 2004 May;11(10):1285-1298.
Mátyus, P. ; Dajka-Halász, B. ; Földi, A. ; Haider, N. ; Barlocco, D. ; Magyar, K. / Semicarnazide-sensitive amine oxidase : Current status and perspectives. In: Current Medicinal Chemistry. 2004 ; Vol. 11, No. 10. pp. 1285-1298.
@article{320f2e51adc748318642c24057cbb0df,
title = "Semicarnazide-sensitive amine oxidase: Current status and perspectives",
abstract = "Semicarbazide-sensitive amine-oxidase (SSAO) is present in various human tissues and in plasma. Oxidative deamination of short-chain aliphatic amines is catalyzed by this enzyme to afford the corresponding aldehydes, ammonia and hydrogen peroxide. Methylamine and aminoacetone have been recognized to be physiological substrates for SSAO. There are several pathological states where increased serum SSAO activity have been found, such as diabetes mellitus, congestive heart failure, multiple types of cerebral infarction, uraemia, and hepatic cirrhosis. The role of SSAO in pathophysiology of diabetes has been most extensively investigated. The elevated formation of the potentially cytotoxic products of the enzyme may contribute to the endothelial injury of blood vessels, resulting in the early development of severe atherosclerosis; it may also contribute to the pathogenesis of diabetic angiopathy. It is now suggested that SSAO inhibitors may prevent the development of atherosclerosis and diabetic complications as well. Inhibitors can be conveniently subdivided into the main groups of hydrazine derivatives, arylalkylamines, propenyl- and propargylamines, oxazolidinones, and haloalkylamines. Of them, aryl(alkyl)hydrazines, and 3-halo-2-phenylallylamines are generally very strong SSAO inhibitors. Most of these inhibitors of SSAO have been originally developed for other purposes, or they are simple chemical reagents with highly reactive structural element(s); these compounds have not been able to fulfil all criteria of high potency, selectivity, and acceptable toxicity. New potent compounds with selectivity and low toxicity are needed, which may prove useful tools for understanding the roles and function of SSAO, or they may even be valuable substances for treatment of various diseases.",
keywords = "Atherosclerosis, Diabetes, Haloalkylamines, Haloallylamines, Hydrazines, Inhibitors, Semicarbazide-sensitive amine oxidase (ssao), VAP-1",
author = "P. M{\'a}tyus and B. Dajka-Hal{\'a}sz and A. F{\"o}ldi and N. Haider and D. Barlocco and K. Magyar",
year = "2004",
month = "5",
language = "English",
volume = "11",
pages = "1285--1298",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Semicarnazide-sensitive amine oxidase

T2 - Current status and perspectives

AU - Mátyus, P.

AU - Dajka-Halász, B.

AU - Földi, A.

AU - Haider, N.

AU - Barlocco, D.

AU - Magyar, K.

PY - 2004/5

Y1 - 2004/5

N2 - Semicarbazide-sensitive amine-oxidase (SSAO) is present in various human tissues and in plasma. Oxidative deamination of short-chain aliphatic amines is catalyzed by this enzyme to afford the corresponding aldehydes, ammonia and hydrogen peroxide. Methylamine and aminoacetone have been recognized to be physiological substrates for SSAO. There are several pathological states where increased serum SSAO activity have been found, such as diabetes mellitus, congestive heart failure, multiple types of cerebral infarction, uraemia, and hepatic cirrhosis. The role of SSAO in pathophysiology of diabetes has been most extensively investigated. The elevated formation of the potentially cytotoxic products of the enzyme may contribute to the endothelial injury of blood vessels, resulting in the early development of severe atherosclerosis; it may also contribute to the pathogenesis of diabetic angiopathy. It is now suggested that SSAO inhibitors may prevent the development of atherosclerosis and diabetic complications as well. Inhibitors can be conveniently subdivided into the main groups of hydrazine derivatives, arylalkylamines, propenyl- and propargylamines, oxazolidinones, and haloalkylamines. Of them, aryl(alkyl)hydrazines, and 3-halo-2-phenylallylamines are generally very strong SSAO inhibitors. Most of these inhibitors of SSAO have been originally developed for other purposes, or they are simple chemical reagents with highly reactive structural element(s); these compounds have not been able to fulfil all criteria of high potency, selectivity, and acceptable toxicity. New potent compounds with selectivity and low toxicity are needed, which may prove useful tools for understanding the roles and function of SSAO, or they may even be valuable substances for treatment of various diseases.

AB - Semicarbazide-sensitive amine-oxidase (SSAO) is present in various human tissues and in plasma. Oxidative deamination of short-chain aliphatic amines is catalyzed by this enzyme to afford the corresponding aldehydes, ammonia and hydrogen peroxide. Methylamine and aminoacetone have been recognized to be physiological substrates for SSAO. There are several pathological states where increased serum SSAO activity have been found, such as diabetes mellitus, congestive heart failure, multiple types of cerebral infarction, uraemia, and hepatic cirrhosis. The role of SSAO in pathophysiology of diabetes has been most extensively investigated. The elevated formation of the potentially cytotoxic products of the enzyme may contribute to the endothelial injury of blood vessels, resulting in the early development of severe atherosclerosis; it may also contribute to the pathogenesis of diabetic angiopathy. It is now suggested that SSAO inhibitors may prevent the development of atherosclerosis and diabetic complications as well. Inhibitors can be conveniently subdivided into the main groups of hydrazine derivatives, arylalkylamines, propenyl- and propargylamines, oxazolidinones, and haloalkylamines. Of them, aryl(alkyl)hydrazines, and 3-halo-2-phenylallylamines are generally very strong SSAO inhibitors. Most of these inhibitors of SSAO have been originally developed for other purposes, or they are simple chemical reagents with highly reactive structural element(s); these compounds have not been able to fulfil all criteria of high potency, selectivity, and acceptable toxicity. New potent compounds with selectivity and low toxicity are needed, which may prove useful tools for understanding the roles and function of SSAO, or they may even be valuable substances for treatment of various diseases.

KW - Atherosclerosis

KW - Diabetes

KW - Haloalkylamines

KW - Haloallylamines

KW - Hydrazines

KW - Inhibitors

KW - Semicarbazide-sensitive amine oxidase (ssao)

KW - VAP-1

UR - http://www.scopus.com/inward/record.url?scp=7444237590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444237590&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1285

EP - 1298

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 10

ER -